Current insights on PSMA PET/CT in intermediate-risk prostate cancer: a literature review

IF 2.5 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Annals of Nuclear Medicine Pub Date : 2025-01-15 DOI:10.1007/s12149-025-02015-w

Priscilla Guglielmo, Nicolò Buffi, Angelo Porreca, Lucia Setti, Demetrio Aricò, Lorenzo Muraglia, Laura Evangelista

{"title":"Current insights on PSMA PET/CT in intermediate-risk prostate cancer: a literature review","authors":"Priscilla Guglielmo, Nicolò Buffi, Angelo Porreca, Lucia Setti, Demetrio Aricò, Lorenzo Muraglia, Laura Evangelista","doi":"10.1007/s12149-025-02015-w","DOIUrl":null,"url":null,"abstract":"<div><p>The purpose of this systematic review was to evaluate the role of PSMA PET/CT in intermediate-risk prostate cancer (PCa) patients, to determine whether it could help improve treatment strategy and prognostic stratification. A systematic literature search up to May 2024 was conducted in the PubMed, Embase and Scopus databases. Articles with mixed risk patient populations, review articles, editorials, letters, comments, or case reports were excluded. The quality of the papers was assessed by using the CASP criteria. The literature search returned 1111 studies; however, 1105 articles were excluded, and therefore 6 full-text papers were retrieved for the final analysis. Three out of six papers focused on the utility of SUVmax in identifying high ISUP grade in patients with intermediate-risk PCa. The latest three papers discussed the controversial role of PSMA PET/CT in predicting the lymph node involvement, mainly in the case of favorable subset. PSMA PET has completely changed the management of patients with PCa; indeed its role is still undefined in patients with intermediate-risk disease. Future perspective is to investigate larger cohorts of intermediate-risk PCa patients, to fully recognize the added value offered by PSMA PET in this category of subjects.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"39 3","pages":"247 - 254"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12149-025-02015-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

The purpose of this systematic review was to evaluate the role of PSMA PET/CT in intermediate-risk prostate cancer (PCa) patients, to determine whether it could help improve treatment strategy and prognostic stratification. A systematic literature search up to May 2024 was conducted in the PubMed, Embase and Scopus databases. Articles with mixed risk patient populations, review articles, editorials, letters, comments, or case reports were excluded. The quality of the papers was assessed by using the CASP criteria. The literature search returned 1111 studies; however, 1105 articles were excluded, and therefore 6 full-text papers were retrieved for the final analysis. Three out of six papers focused on the utility of SUVmax in identifying high ISUP grade in patients with intermediate-risk PCa. The latest three papers discussed the controversial role of PSMA PET/CT in predicting the lymph node involvement, mainly in the case of favorable subset. PSMA PET has completely changed the management of patients with PCa; indeed its role is still undefined in patients with intermediate-risk disease. Future perspective is to investigate larger cohorts of intermediate-risk PCa patients, to fully recognize the added value offered by PSMA PET in this category of subjects.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

PSMA PET/CT在中危前列腺癌中的研究进展：文献综述。

本系统综述的目的是评估PSMA PET/CT在中危前列腺癌（PCa）患者中的作用，以确定它是否有助于改善治疗策略和预后分层。在PubMed、Embase和Scopus数据库中系统检索截至2024年5月的文献。含有混合风险患者人群的文章、综述文章、社论、信件、评论或病例报告被排除在外。采用CASP标准对论文质量进行评估。文献检索得到1111项研究；然而，有1105篇文章被排除在外，因此有6篇全文论文被检索用于最终分析。六篇论文中有三篇聚焦于SUVmax在识别中危PCa患者高ISUP分级中的应用。最近的三篇论文讨论了PSMA PET/CT在预测淋巴结受累方面的争议性作用，主要是在有利亚群的情况下。PSMA PET彻底改变了PCa患者的管理；事实上，它在中等风险疾病患者中的作用仍不明确。未来的观点是研究更大的中危PCa患者队列，以充分认识PSMA PET在这类受试者中提供的附加价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Annals of Nuclear Medicine 医学-核医学

CiteScore

4.90

自引率

7.70%

发文量

111

审稿时长

4-8 weeks

期刊介绍： Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine. The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.